HMN-214

• Product Name Alternative:

  IVX-214

• UNSPSC Description:

  HMN-214, an orally bioavailable proagent of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.

• Target Antigen:

  Polo-like Kinase (PLK)

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/HMN-214.html

• Purity:

  99.16

• Solubility:

  DMSO : 8.33 mg/mL (ultrasonic)

• Smiles:

  CC(N(S(=O)(C1=CC=C(OC)C=C1)=O)C2=CC=CC=C2/C=C/C3=CC=[N+]([O-])C=C3)=O

• Molecular Weight:

  424.47

• References & Citations:

  [1]Takagi M, et al. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs. 2003 Nov;21(4):387-99.|[2]Garland LL, et al. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res. 2006 Sep 1;12(17):5182-9.|[3]Tanaka H, et al. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res. 2003 Oct 15;63(20):6942-7.|[4]Christensen MD, et al. Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression. J Control Release. 2015 Apr 28;204:20-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 1

• CAS Number:

  173529-46-9